About Hybio Pharmaceutical
Hybio Pharmaceutical is a company based in Shenzhen (China) founded in 1998.. Hybio Pharmaceutical has raised $15 million across 1 funding round from investors including Shenzhen Capital Group. Hybio Pharmaceutical has completed 1 acquisition, including AMW Pharmaceuticals. Hybio Pharmaceutical operates in a competitive market with competitors including Enzene Biosciences, AmbioPharm, Ocelot Bio, Rameda and Shaanxi Micot Technology, among others.
- Headquarter Shenzhen, China
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hybio Pharmaceutical Co., Ltd. Class A
-
Annual Revenue
$80.86 M (USD)40.95as on Dec 31, 2024
-
Net Profit
$-24.72 M (USD)64.89as on Dec 31, 2024
-
EBITDA
-
Total Equity Funding
$15 M (USD)
in 1 rounds
-
Latest Funding Round
$15 M (USD), Series A
Mar 19, 2008
- Investors
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Hybio Pharmaceutical
Hybio Pharmaceutical is a publicly listed company on the SZSE with ticker symbol 300199 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Hybio Pharmaceutical
Hybio Pharmaceutical has successfully raised a total of $15M through 1 strategic funding round. The most recent funding activity was a Series A round of $15 million completed in March 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $15.0M
-
First Round
First Round
(19 Mar 2008)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2008 | Amount | Series A - Hybio Pharmaceutical | Valuation | Shenzhen Capital Group |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Hybio Pharmaceutical
Hybio Pharmaceutical has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Shenzhen Capital Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital, equity investment, and fund management services in China.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hybio Pharmaceutical
Hybio Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AMW Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Transdermal drug delivery technologies are developed and manufactured for therapeutics.
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Hybio Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hybio Pharmaceutical Comparisons
Competitors of Hybio Pharmaceutical
Hybio Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enzene Biosciences, AmbioPharm, Ocelot Bio, Rameda and Shaanxi Micot Technology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Company specializing in development of Biosimilars
|
|
| domain | founded_year | HQ Location |
CDMO and analytical services for peptide development are provided.
|
|
| domain | founded_year | HQ Location |
Ocelot Bio is a CDMO specializing in peptide manufacturing services.
|
|
| domain | founded_year | HQ Location |
Developer and manufacturer of generic pharmaceuticals, nutraceuticals, food supplements and veterinary products
|
|
| domain | founded_year | HQ Location |
Drug R&D services for cardiovascular and metabolic diseases are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hybio Pharmaceutical
Frequently Asked Questions about Hybio Pharmaceutical
When was Hybio Pharmaceutical founded?
Hybio Pharmaceutical was founded in 1998 and raised its 1st funding round 10 years after it was founded.
Where is Hybio Pharmaceutical located?
Hybio Pharmaceutical is headquartered in Shenzhen, China. It is registered at Shenzhen, Guangdong, China.
Who is the current CEO of Hybio Pharmaceutical?
Jiancheng Yuan is the current CEO of Hybio Pharmaceutical.
Is Hybio Pharmaceutical a funded company?
Hybio Pharmaceutical is a funded company, having raised a total of $15M across 1 funding round to date. The company's 1st funding round was a Series A of $15M, raised on Mar 19, 2008.
What is the annual revenue of Hybio Pharmaceutical?
Annual revenue of Hybio Pharmaceutical is $80.86M as on Dec 31, 2024.
What does Hybio Pharmaceutical do?
Hybio Pharmaceutical was founded in 1998 and is based in Shenzhen, China. Operations focus on the pharmaceutical sector, with a portfolio that includes Desmopressin acetate, Thymopentin, Somatostatin, and Terlipressin. Customers are served in the US, Canada, Italy, India, Germany, and Russia. Custom peptide synthesis services are offered through CROCDO models, alongside GMP-compliant CMO capabilities for peptide production.
Who are the top competitors of Hybio Pharmaceutical?
Hybio Pharmaceutical's top competitors include Enzene Biosciences, PolyPeptide and AmbioPharm.
Is Hybio Pharmaceutical publicly traded?
Yes, Hybio Pharmaceutical is publicly traded on SZSE under the ticker symbol 300199.
How many acquisitions has Hybio Pharmaceutical made?
Hybio Pharmaceutical has made 1 acquisition, including AMW Pharmaceuticals.
Who are Hybio Pharmaceutical's investors?
Hybio Pharmaceutical has 1 investor. Key investors include Shenzhen Capital Group.
What is Hybio Pharmaceutical's ticker symbol?
The ticker symbol of Hybio Pharmaceutical is 300199 on SZSE.